User:Mr. Ibrahem/Trospium

Mr. Ibrahem/Trospium
Clinical data
Trade namesRegurin, Sanctura, others[1]
AHFS/Drugs.comMonograph
Pregnancy
category
  • C
Routes of
administration		By mouth (tablets, capsules)
Drug classAntimuscarinic agent[2]
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding50–85%
Onset of actionWithin 7 days[3]
Elimination half-life20 hours
Identifiers
  • 3‑(2‑Hydroxy-2,2‑diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,1'‑pyrrolidin]-1'‑ium chloride
Chemical and physical data
FormulaC25H30ClNO3
Molar mass427.97 g·mol−1
3D model (JSmol)
  • Interactive image
  • OC(c1ccccc1)(c2ccccc2)C(=O)O[C@@H]3C[C@@H]5CC[C@H](C3)[N+]45CCCC4
  • InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1/t21-,22+,23+ checkY
  • Key:OYYDSUSKLWTMMQ-JKHIJQBDSA-N checkY
  (verify)

Trospium, sold under the brand name Sanctura among others, is a medication used to treat symptoms of overactive bladder.[4] It is taken by mouth.[4] Effects begin within 7 days.[3]

Common side effects include dry mouth, abdominal pain, and constipation.[4][5] Other side effects may include urinary retention, agitation, and anaphylaxis.[4][5] Safety in pregnancy is unclear.[6] It is a antimuscarinic agent with minimal effects on the central nervous system.[2] It works by causing the smooth muscle in the bladder to relax.[7]

Trospium was patented in 1966 and approved for medical use in 1974.[8] It is available as a generic medication.[5] In the United Kingdom a month of medication costs the NHS about £6 in 2021.[5] In the United States this amount costs about 30 USD.[9]

References

  1. ^ Drugs.com international brands of trospium Archived 2019-10-22 at the Wayback Machine Page accessed May 13, 2016
  2. ^ a b Biastre K, Burnakis T (February 2009). "Trospium chloride treatment of overactive bladder". Ann Pharmacother. 43 (2): 283–95. doi:10.1345/aph.1L160. PMID 19193592. S2CID 20102756.
  3. ^ a b Kreder, Karl; Dmochowski, Roger (10 July 2007). The Overactive Bladder: Evaluation and Management. CRC Press. p. 193. ISBN 978-0-203-93162-2. Archived from the original on 23 September 2021. Retrieved 20 September 2021.
  4. ^ a b c d e f g "Trospium Monograph for Professionals". Drugs.com. Archived from the original on 20 January 2021. Retrieved 20 September 2021.
  5. ^ a b c d e BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 824. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  6. ^ "Trospium Use During Pregnancy". Drugs.com. Archived from the original on 3 December 2020. Retrieved 20 September 2021.
  7. ^ "Regurin XL 60mg - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Archived from the original on 17 January 2021. Retrieved 20 September 2021.
  8. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 446. ISBN 9783527607495. Archived from the original on 2020-11-15. Retrieved 2021-03-16.
  9. ^ "Trospium Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 10 April 2021. Retrieved 20 September 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Trospium&oldid=1195305839"